Wormwood for Crohn's Disease and Inflammation

This is the one place where wormwood has genuine randomized human evidence, and it is worth spelling out exactly what that evidence is — because it is simultaneously more interesting than most herbal research and much smaller than the internet suggests. Two controlled trials, both from a German research group, both in Crohn's disease, reported that a wormwood preparation added to standard care allowed patients to come off corticosteroids while their symptoms continued to improve, and that it lowered the inflammatory cytokine TNF-alpha. Together those two studies involved fewer than sixty people.

That is a real finding and a thin base. This page walks through both trials, what preparation and dose were used, why steroid-sparing is the outcome that made gastroenterologists look twice, and what the near-absence of independent replication in the years since should do to your confidence.

Table of Contents

1. First: the Right Plant
2. Crohn's Disease and Why Steroid-Sparing Matters
3. The 2007 Double-Blind Placebo-Controlled Trial
4. The 2010 Controlled Trial and TNF-alpha
5. How Strong Is This Evidence, Really
6. Which Preparation and Dose Were Tested
7. Plausible Mechanisms
8. What Standard Crohn's Treatment Looks Like
9. How to Raise This With Your Gastroenterologist
10. Ulcerative Colitis and Other Inflammatory Conditions
11. Risks That Matter Specifically in IBD
12. Key Research Papers
13. Connections

First: the Right Plant

The trials described here used Artemisia absinthium — common wormwood, the bitter absinthe herb. They did not use Artemisia annua (sweet wormwood) and they had nothing to do with artemisinin. There is separate research interest in artemisinin derivatives for inflammatory conditions, but it is a different compound from a different species with a different safety profile, and it belongs on the Artemisia annua page. Do not substitute one for the other on the strength of a shared common name.

Crohn's Disease and Why Steroid-Sparing Matters

Crohn's disease is a chronic immune-mediated inflammatory bowel disease that can affect any part of the digestive tract, from mouth to anus, typically in patches and often through the full thickness of the bowel wall. It runs in flares and remissions and it is not curable with current treatment; the goal of therapy is durable remission with healing of the bowel lining.

Corticosteroids — prednisone, prednisolone, budesonide — are excellent at putting out a flare and terrible as long-term therapy. Extended steroid use brings weight gain, mood and sleep disturbance, high blood sugar and steroid-induced diabetes, cataracts and glaucoma, thinning skin, adrenal suppression, infection risk and, most consequentially over years, bone loss. Because of this, modern guidelines treat steroids as a bridge and consider "steroid dependence" — the inability to taper without relapsing — a treatment failure in its own right.

That is the context that makes the wormwood trials interesting. Their primary claim is not "wormwood treats Crohn's disease." It is steroid-sparing: that patients on the herb were able to complete a steroid taper without the relapse that usually accompanies it. In IBD research, a credible steroid-sparing agent is a genuinely valuable thing, which is why a small phytotherapy trial got noticed at all.

The 2007 Double-Blind Placebo-Controlled Trial

The primary study is Omer, Krebs, Omer and Noor, "Steroid-sparing effect of wormwood (Artemisia absinthium) in Crohn's disease: a double-blind placebo-controlled study," published in Phytomedicine in 2007. Evidence tier: randomized clinical trial — small, single-centre.

The design, in outline:

• Around forty adults with Crohn's disease, split roughly evenly between a wormwood preparation and a matching placebo.
• All participants were on corticosteroids at entry and continued their other Crohn's medication — this was an add-on study, not a comparison of wormwood against drug therapy.
• Steroids were then tapered on a fixed schedule in both arms, which is the mechanism of the whole experiment: reduce the drug in everybody and see which group holds.
• Total duration was around ten weeks, with disease activity tracked by standard Crohn's activity scoring and with mood also assessed.

The reported result was that in the wormwood arm the great majority of patients completed the taper with symptoms continuing to improve, while the placebo arm largely deteriorated as their steroid dose came down — the expected pattern when a steroid crutch is removed with nothing replacing it. The paper also reported improvement in mood scores in the wormwood group, which the authors noted was not simply explained by the improvement in bowel symptoms. For exact participant counts and effect sizes, read the paper itself rather than any summary, including this one.

The 2010 Controlled Trial and TNF-alpha

The follow-up is Krebs, Omer and Omer, "Wormwood (Artemisia absinthium) suppresses tumour necrosis factor alpha and accelerates healing in patients with Crohn's disease — a controlled clinical trial," Phytomedicine, 2010. Evidence tier: randomized clinical trial — very small.

This study enrolled roughly twenty patients and asked a mechanistic question rather than a purely symptomatic one. Alongside clinical activity it measured serum TNF-alpha, the pro-inflammatory cytokine that is the direct target of the anti-TNF biologic drugs (infliximab, adalimumab) that transformed IBD treatment. The report was that TNF-alpha fell in the wormwood group relative to control, accompanied by clinical improvement and evidence of healing of the intestinal lining.

Why this matters more than a symptom score: TNF-alpha is a hard biological readout that is difficult to move by suggestion, and mucosal healing is the outcome modern IBD care actually aims at. A herb that plausibly nudges the same axis as an anti-TNF drug is a legitimate research lead. Twenty patients is also, bluntly, twenty patients.

How Strong Is This Evidence, Really

Here is the honest audit. Every one of these points is a limitation, and none of them makes the finding worthless.

• Sample size. Roughly forty and roughly twenty participants. Trials this small produce unstable effect estimates and are prone to overstating benefit; regulators would treat either as a pilot.
• One research group. Both trials share authors. Independent replication by unrelated investigators is the thing that turns a promising result into a reliable one, and that step has largely not happened.
• Limited replication since. In the years after 2010, wormwood in Crohn's disease has been repeatedly cited in reviews of herbal therapy for IBD — for example Ng and colleagues, "Systematic review: the efficacy of herbal therapy in inflammatory bowel disease," Alimentary Pharmacology & Therapeutics, 2013, and Langhorst and colleagues, "Systematic review of complementary and alternative medicine treatments in inflammatory bowel diseases," Journal of Crohn's and Colitis, 2015 — but citation is not replication. Reviews keep pointing at the same two small studies.
• Short duration. Weeks, not years. Crohn's disease is measured in decades. Nothing here speaks to maintenance of remission, and nothing speaks to the safety of taking a thujone-containing herb continuously for a long period.
• Add-on design. Every participant remained on conventional therapy. These trials never tested wormwood as a replacement for medication, and nobody should read them that way.
• Proprietary preparation. The tested product was a specific preparation. A random capsule of dried wormwood from a shop is not the studied intervention.

The fair summary: a real, positive, biologically coherent randomized signal in a serious disease, at pilot scale, awaiting the replication that would make it actionable. That is a much better position than most herbs occupy and a much worse one than a proven therapy.

Which Preparation and Dose Were Tested

This section matters because the gap between the trial dose and the traditional bitters dose is large enough to change the safety conversation.

The trials used a proprietary standardized preparation of dried wormwood herb, taken in divided doses several times a day. The total daily quantity of dried herb was in the region of a couple of grams — roughly an order of magnitude more than the few drops of dilute tincture used as a pre-meal digestive bitter (see Wormwood for Digestion and the Bitter Reflex). Consult the published papers for the precise formulation and milligram dose before drawing conclusions from any number quoted second-hand.

Three consequences follow:

1. The thujone exposure is not trivial at trial dose. A whole-herb powder at grams per day for weeks delivers far more thujone than a splash of vermouth. The trials reported acceptable tolerability over their short duration; that is not the same as establishing safety for months or years. See Thujone, Absinthe and Dose Limits.
2. Products are not interchangeable. Thujone and bitter-lactone content vary enormously with plant origin, chemotype and harvest — documented for the essential oil by Juteau and colleagues in Planta Medica, 2003. Two "wormwood 500 mg" capsules from different suppliers can differ substantially in the constituents that matter.
3. Essential oil is not a shortcut to the trial dose. The oil was not what was tested and must never be taken internally. Acute renal failure from ingested wormwood oil is documented in the New England Journal of Medicine case report by Weisbord, Soule and Kimmel, 1997.

Plausible Mechanisms

How could a bitter herb affect immune-mediated bowel inflammation? Several routes are plausible; all are preliminary as applied to Crohn's disease in people.

• Sesquiterpene lactones and NF-kB. Wormwood is rich in sesquiterpene lactones, a class known more broadly for inhibiting NF-kB signalling — the master switch that drives transcription of TNF-alpha and other inflammatory mediators. This is the most cited candidate explanation and it fits the TNF-alpha result. It is inferred from the chemical class, not demonstrated for wormwood in human bowel tissue.
• Flavonoids and phenolic acids. The whole herb supplies quercetin-type flavonoids and chlorogenic-acid relatives with antioxidant and anti-inflammatory activity in cell systems.
• Bitter-receptor and gut-hormone effects. TAS2R receptors on enteroendocrine cells influence motility and hormone release, and some evidence suggests bitter signalling interacts with mucosal immune function. Speculative in this context.
• Effects on the gut microbiota. Wormwood extracts have antimicrobial activity in vitro, and microbial composition is central to Crohn's pathogenesis. Attractive, entirely untested here, and cuts both ways — an antimicrobial herb could as easily disturb a fragile microbiome as improve it.
• Mood as a mediator, or as an effect. The 2007 report of improved mood raises a real question. Thujone's activity at the GABA-A receptor is central-nervous-system activity by definition, and the brain-gut axis is not a metaphor in IBD. Whether the mood change contributed to the symptom improvement, resulted from it, or is a separate central effect is unresolved.

What Standard Crohn's Treatment Looks Like

Included because a page like this should never leave a reader thinking herbs are the state of the art. Crohn's treatment has improved enormously and the options are real:

• Corticosteroids (prednisone, prednisolone, or ileal-release budesonide) to induce remission in a flare — effective short-term, not for maintenance.
• Thiopurines (azathioprine, mercaptopurine) and methotrexate as conventional immunomodulators for maintenance.
• Anti-TNF biologics (infliximab, adalimumab) — the drugs that target the same cytokine the 2010 wormwood trial measured.
• Anti-integrin therapy (vedolizumab), gut-selective.
• Anti-interleukin therapy (ustekinumab targeting IL-12/23; risankizumab targeting IL-23).
• Oral small molecules such as the JAK inhibitor upadacitinib.
• Exclusive enteral nutrition, particularly well established in paediatric Crohn's disease as a genuine alternative to steroids for inducing remission.
• Surgery for strictures, fistulas, abscesses and disease unresponsive to medication — not a failure, often the right answer.
• Smoking cessation, which is one of the highest-value interventions in Crohn's disease specifically and is frequently underemphasized.
• Monitoring with faecal calprotectin, CRP, ESR and periodic endoscopy, so that decisions are based on measured inflammation rather than how someone feels that week.

Wormwood, at its most optimistic reading, is a candidate adjunct that might help someone get off steroids. It is not on this list and does not belong on it yet.

How to Raise This With Your Gastroenterologist

If the steroid-sparing finding interests you — and if you are steroid-dependent, it reasonably might — the productive way to bring it up is specific rather than general.

• Bring the actual papers. The two Phytomedicine trials, by name and year. "I read that wormwood helps Crohn's" invites a brush-off; "there are two small randomized trials reporting a steroid-sparing effect, and I'd like your read on them" invites a conversation.
• Frame it as an add-on, never a substitute. That is what was studied. Stopping prescribed medication to try a herb is how people end up with a stricture or an abscess.
• Declare the thujone issue yourself. Your clinician may not know wormwood contains a convulsant. Say so, and say what preparation and dose you are considering.
• Disclose every other supplement. Interaction and duplication risks in IBD are real, and hepatic monitoring may already be in place because of thiopurines or methotrexate.
• Agree in advance what would count as failure. A defined trial period, an objective marker such as calprotectin or CRP, and a rule for stopping. Open-ended self-experimentation in an inflammatory disease is how silent inflammation progresses to permanent bowel damage.
• Never treat improvement in symptoms as proof of healed bowel. Crohn's disease can be objectively active while someone feels well; this is precisely why calprotectin and endoscopy exist.

Ulcerative Colitis and Other Inflammatory Conditions

People reasonably ask whether the Crohn's result transfers. The honest answers:

• Ulcerative colitis: not tested with wormwood in any comparable trial. UC and Crohn's differ in distribution, depth, immunology and drug response — a result in one does not carry to the other. Other botanicals, notably curcumin as an adjunct to mesalamine, have better UC-specific evidence.
• Rheumatoid arthritis and other systemic inflammatory disease: no meaningful wormwood evidence. TNF-alpha involvement in a disease is not a reason to expect a herb that may lower TNF-alpha in twenty bowel patients to help it.
• Irritable bowel syndrome: a different condition without the inflammation, and not the target of these trials. Peppermint oil has far better evidence there.
• Liver inflammation: the rodent hepatoprotection data (Amat, Upur and Blažeković, Journal of Ethnopharmacology, 2010) is preliminary and does not support human use.

Risks That Matter Specifically in IBD

The general wormwood cautions all apply — pregnancy, epilepsy, kidney disease, daisy-family allergy, never the essential oil — and are set out in full on the safety page. Some points bite harder in inflammatory bowel disease:

• Absorption is not normal in active disease. Inflamed or resected bowel handles compounds unpredictably. A dose calibrated on healthy volunteers may not behave the same way.
• Pregnancy is a hard stop, and this population is disproportionately affected. Crohn's disease commonly presents in people of reproductive age; wormwood's emmenagogue and abortifacient tradition and thujone's developmental concerns mean it must be avoided in pregnancy, while trying to conceive, and while breastfeeding.
• Liver monitoring overlaps with existing drugs. Thiopurines and methotrexate already require liver monitoring; adding a herb with an incompletely characterized hepatic profile makes any abnormal liver function test harder to attribute.
• Alcohol-based tinctures are a poor vehicle in liver disease and in anyone avoiding alcohol.
• Delayed escalation is the biggest hazard of all. The real harm of herbal self-treatment in Crohn's disease is rarely direct toxicity — it is months of unaddressed inflammation while someone tries alternatives, ending in a stricture or surgery that earlier escalation would have avoided.
• Do not use during a severe flare in place of urgent care. Severe abdominal pain, fever, obstruction, heavy bleeding or systemic illness is an emergency.

Key Research Papers

Linked as PubMed searches so the link cannot drift onto the wrong record. Titles, journals and years are given for verification.

1. Omer, Krebs, Omer and Noor, "Steroid-sparing effect of wormwood (Artemisia absinthium) in Crohn's disease: a double-blind placebo-controlled study," Phytomedicine, 2007 — the primary trial. Randomized clinical trial, roughly forty participants.
2. Krebs, Omer and Omer, "Wormwood (Artemisia absinthium) suppresses tumour necrosis factor alpha and accelerates healing in patients with Crohn's disease — a controlled clinical trial," Phytomedicine, 2010 — the follow-up with a biomarker endpoint. Randomized clinical trial, roughly twenty participants.
3. Ng and colleagues, "Systematic review: the efficacy of herbal therapy in inflammatory bowel disease," Alimentary Pharmacology & Therapeutics, 2013 — positions wormwood among the IBD botanicals. Systematic review.
4. Langhorst and colleagues, "Systematic review of complementary and alternative medicine treatments in inflammatory bowel diseases," Journal of Crohn's and Colitis, 2015 — broader CAM appraisal, same two source trials. Systematic review.
5. Rahimi and colleagues, review of traditional Iranian medicine for inflammatory bowel disease, World Journal of Gastroenterology, 2010 — the ethnopharmacological context for bitter Artemisia use in gut disease. Traditional use only.
6. PubMed topic search: Artemisia absinthium and Crohn's disease, all study types — run this to see for yourself how short the list of primary trials still is.
7. Szopa and colleagues, "Artemisia absinthium L. — importance in the history of medicine, the latest advances in phytochemistry and therapeutical, cosmetological and culinary uses," Plants, 2020 — the sesquiterpene-lactone chemistry behind the anti-inflammatory hypothesis. Review.
8. Batiha and colleagues, "Bioactive compounds, pharmacological actions, and pharmacokinetics of wormwood (Artemisia absinthium)," Antibiotics, 2020 — pharmacology and what little is known of the pharmacokinetics. Review.
9. Amat, Upur and Blažeković, "In vivo hepatoprotective activity of the aqueous extract of Artemisia absinthium L. against chemically and immunologically induced liver injuries in mice," Journal of Ethnopharmacology, 2010 — preliminary (mice), including an immunologically induced injury model.
10. Höld and colleagues, "Alpha-thujone (the active component of absinthe): gamma-aminobutyric acid type A receptor modulation and metabolic detoxification," PNAS, 2000 — why a grams-per-day whole-herb dose is not a free lunch.
11. Weisbord, Soule and Kimmel, "Poison on line — acute renal failure caused by oil of wormwood purchased through the Internet," New England Journal of Medicine, 1997 — human, non-randomized (case report).
12. Lachenmeier, "Wormwood (Artemisia absinthium L.) — a curious plant with both neurotoxic and neuroprotective properties?," Journal of Ethnopharmacology, 2010 — explicitly weighs the Crohn's findings against the toxicity record.

Back to Table of Contents

Connections

• All Herbs
• Crohn's Disease — the condition itself, diagnosis and treatment.
• Ulcerative Colitis — the other major IBD, where wormwood is untested.
• Gastroenterology — digestive disease overview.
• SIBO — common overlap in Crohn's disease, especially after resection.
• Immunology — immune-mediated disease background.
• Wormwood — the main overview page.
• Wormwood Benefits Hub — all four deep dives.
• Thujone, Absinthe and Dose Limits — the safety ceiling on trial-level dosing.
• Wormwood for Digestion — how much smaller a bitters dose is.
• Artemisia annua (Sweet Wormwood) — the species these trials did not use.
• Boswellia — another botanical studied as an IBD adjunct.
• Milk Thistle — liver support, relevant alongside IBD drug monitoring.
• Chamomile — daisy-family relative; shares the allergy caution.
• hs-CRP — inflammatory marker used to follow disease activity.
• ESR Test — the other common inflammation marker.
• Liver Function Tests — monitoring while on immunomodulators and herbs.
• Epilepsy — contraindication that rules wormwood out entirely for some patients.

Educational information only, not medical advice. Wormwood is not an approved or established treatment for Crohn's disease. The two trials described here were small, came from a single research group, ran for weeks rather than years, and tested wormwood added to conventional therapy — never as a replacement for it. Do not stop or reduce prescribed Crohn's medication to try a herb. Wormwood must not be used in pregnancy or breastfeeding, or by anyone with epilepsy or a seizure disorder; the essential oil must never be taken internally. Discuss any herbal addition with your gastroenterologist, and keep monitoring objective inflammation rather than relying on how you feel.

Back to Table of Contents